Working… Menu

Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00376636
Recruitment Status : Completed
First Posted : September 15, 2006
Last Update Posted : October 30, 2007
Information provided by:
Speedel Pharma Ltd.

Brief Summary:
This study is conducted to investigate the effect of the oral renin inhibitor SPP635 on blood pressure in patients with mild to moderate hypertension.

Condition or disease Intervention/treatment Phase
Hypertension Drug: SPP635 (drug) Phase 2

Detailed Description:
Renin-Angiotensin system blockade is a well established target for treatment of high blood pressure. Blocking the system at the initial step, however, is a rather new concept that could only be implemented very recently through the availability of novel, oral, renin inhibitors. This study investigates the safety and efficacy of a novel oral renin inhibitor, SPP635.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Parallel-Design, Four-Week Study to Investigate the Safety and Efficacy of the Oral Renin Inhibitor SPP635 Once Daily in Patients With Mild to Moderate Hypertension
Study Start Date : October 2006
Actual Study Completion Date : May 2007

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Lowering of systolic office blood pressure [ Time Frame: four weeks ]
  2. Lowering of diastolic office blood pressure [ Time Frame: four weeks ]

Secondary Outcome Measures :
  1. Lowering of systolic and diastolic blood pressure (ABPM) [ Time Frame: four weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • male or female patients with mild to moderate hypertension

Exclusion Criteria:

  • female patients of child-bearing potential or breast-feeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00376636

Layout table for location information
IKP Bobenheim GmbH
Mannheim, Germany, 68167
Sponsors and Collaborators
Speedel Pharma Ltd.
Layout table for investigator information
Principal Investigator: Sybille Baumann-Noss, MD IKP Bobenheim GmbH
Layout table for additonal information Identifier: NCT00376636    
Other Study ID Numbers: SPP635CRD04
First Posted: September 15, 2006    Key Record Dates
Last Update Posted: October 30, 2007
Last Verified: September 2006
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases